Skip to content

Study · Animal study (in vivo) · rat · 2011

5 results

[The absence of tolerance and withdrawal syndrome after the treatment with the new L-tryptophane-containing dipeptide anxiolytic GB-115].

Kolik LG, Garibova TL, Litvinova SA, Kuznetsova AL, Kapitsa IG, Kadnikov IA, Konstantinopol'skiĭ MA, Gudasheva TA, Voronina TA, Seredenin SB

Vestnik Rossiiskoi akademii meditsinskikh nauk1 Jan 2011

PMID21899090 (opens in a new tab)PepBankPUB-21899090
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, GB‑115 retained anxiolytic properties after daily intraperitoneal treatment for 30 days.

    In plain wordsIn rats, GB‑115 retained its anxiety-reducing effect after daily treatment for 30 days.

    Peptide
    GB-115
    Outcome
    Not applicableRetention of anxiolytic effect
    Study

    ratn: not reported in source

    Chronic GB-115 administration and withdrawal
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    0.1 mg/kg daily · intraperitoneal · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    It was shown using the "elevated plus-maze" test (EPM) that GB-115 retained its anxiolytic properties after i/p injections at a daily dose of 0.1 mg/kg fo r 30-days.
    1 context sentence
    Summary · context
    Effects of GB-115, an anxiolytic L-triptophan-containing dipeptide, based on the endogenous tetrapeptide cholecystokinin, were evaluated during and after withdrawal of its long-term administration to rats in comparison with diazepam.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In rats, GB‑115 discontinuation did not produce increased anxiety as a withdrawal manifestation.

    In plain wordsIn rats, GB‑115 withdrawal did not increase anxiety.

    Peptide
    GB-115
    Outcome
    No significant changeAnxiety after withdrawal
    Study

    ratn: not reported in source

    Chronic GB-115 administration and withdrawal
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    0.1 mg/kg daily · intraperitoneal · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    Discontinuation of dipeptide administration 24h and 48 hours after the onset of the experiment did not lead to behavioral (increased anxiety, aggression) and convulsive (decreased corazol sensitivity) manifestations of withdrawal syndrome.
    2 context sentences
    Summary · context
    It was shown using the "elevated plus-maze" test (EPM) that GB-115 retained its anxiolytic properties after i/p injections at a daily dose of 0.1 mg/kg fo r 30-days.
    Summary · context
    Effects of GB-115, an anxiolytic L-triptophan-containing dipeptide, based on the endogenous tetrapeptide cholecystokinin, were evaluated during and after withdrawal of its long-term administration to rats in comparison with diazepam.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In rats, GB‑115 discontinuation did not produce aggression as a withdrawal manifestation.

    In plain wordsIn rats, GB‑115 withdrawal did not produce aggression.

    Peptide
    GB-115
    Outcome
    No significant changeAggression after withdrawal
    Study

    ratn: not reported in source

    Chronic GB-115 administration and withdrawal
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    0.1 mg/kg daily · intraperitoneal · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    Discontinuation of dipeptide administration 24h and 48 hours after the onset of the experiment did not lead to behavioral (increased anxiety, aggression) and convulsive (decreased corazol sensitivity) manifestations of withdrawal syndrome.
    2 context sentences
    Summary · context
    It was shown using the "elevated plus-maze" test (EPM) that GB-115 retained its anxiolytic properties after i/p injections at a daily dose of 0.1 mg/kg fo r 30-days.
    Summary · context
    Effects of GB-115, an anxiolytic L-triptophan-containing dipeptide, based on the endogenous tetrapeptide cholecystokinin, were evaluated during and after withdrawal of its long-term administration to rats in comparison with diazepam.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In rats, GB‑115 discontinuation did not produce convulsive manifestations of withdrawal syndrome.

    In plain wordsIn rats, GB‑115 withdrawal did not produce convulsive manifestations.

    Peptide
    GB-115
    Outcome
    No significant changeConvulsive withdrawal manifestations
    Study

    ratn: not reported in source

    Chronic GB-115 administration and withdrawal
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    0.1 mg/kg daily · intraperitoneal · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    Discontinuation of dipeptide administration 24h and 48 hours after the onset of the experiment did not lead to behavioral (increased anxiety, aggression) and convulsive (decreased corazol sensitivity) manifestations of withdrawal syndrome.
    2 context sentences
    Summary · context
    It was shown using the "elevated plus-maze" test (EPM) that GB-115 retained its anxiolytic properties after i/p injections at a daily dose of 0.1 mg/kg fo r 30-days.
    Summary · context
    Effects of GB-115, an anxiolytic L-triptophan-containing dipeptide, based on the endogenous tetrapeptide cholecystokinin, were evaluated during and after withdrawal of its long-term administration to rats in comparison with diazepam.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats, significant differences between GB‑115 and diazepam effects on dopamine, norepinephrine, and their metabolites after chronic treatment and withdrawal occurred only in striatum.

    In plain wordsIn rats, GB‑115 and diazepam effects on dopamine, norepinephrine, and their metabolites differed only in striatum after chronic treatment and withdrawal.

    Peptide
    GB-115
    Outcome
    Direction not reportedStriatal monoamine and metabolite differences
    Study

    ratn: not reported in source

    Chronic GB-115 administration and withdrawal
    Comparator
    Diazepam
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    0.1 mg/kg daily · intraperitoneal · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    Significant differences between GB-115 and diazepam effects on the levels of dopamine, norepinephrine, and their metabolites after chronic administration and withdrawal were restricted to striatum.
    1 context sentence
    Summary · context
    Effects of GB-115, an anxiolytic L-triptophan-containing dipeptide, based on the endogenous tetrapeptide cholecystokinin, were evaluated during and after withdrawal of its long-term administration to rats in comparison with diazepam.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.